Questa è la nostra ultima selezione di pubblicazioni e brevetti mondiali in inglese su Biotechnology e CRISPR, tra numerose riviste scientifiche online, classificate e focalizzate su CRISPR, editing genico, gRNA, sequenza PAM, clivaggio del DNA, proteina Cas9, editing del genoma, inserimento genico e knockout genico.
Method for producing blue cheese with penicillium roqueforti strains inactivated for mycotoxins and said strains
Patent published on the 2026-10-08 in WO under Ref WO2026207642 by UNIV DE SANTIAGO DE CHILE [CL] (ChÁvez Rosales Renato Antonio [cl], RodrÍguez EstÉvez Delimary [cl])
Abstract: The present invention relates to microorganisms for which the ability to produce certain mycotoxins has been removed using CRISPR-Cas9 technology. In particular, the invention relates to novel mutant strains of the fungus Penicillium roqueforti, deposit numbers RGM 3700 (M1), RGM 3701 (RM2) and RGM 3702 (R85) of the Chilean Collection of Microbial Genetic Resources (CChRGM), all dated 28 February 2025, for which the ability to produce the mycotoxins roquefortine C (ROQ C) and mycophenolic acid ([...]
Our summary: The invention describes mutant strains of Penicillium roqueforti with mycotoxin production capabilities removed using CRISPR-Cas9 technology. These strains, RGM 3700, RGM 3701, and RGM 3702, can still grow in cheese. They enable the safe production of blue cheese without the risk of mycotoxin contamination.
CRISPR-Cas9, Penicillium roqueforti, mycotoxins, blue cheese
Patent
Universal treatment of down syndrome
Patent published on the 2026-10-01 in US under Ref US20260294978 by DEI BIOPHARMA [UG] (Magoola Matthias [ug])
Abstract: Allele-specific (AS) CRISPR-Cas9-mediated cleavage to induce selective loss of the extra chromosome, particularly in a trisomic context where the dosage imbalance is inherently deleterious, can treat Down Syndrome, an untreatable disorder. While it is suitable for individualized therapy, the instant invention provides a generalized treatment module that can be used for any Down Syndrome patient.[...]
Our summary: This invention utilizes AS CRISPR-Cas9 to selectively target and cleave the extra chromosome in Down Syndrome. It offers a potential treatment option for this previously untreatable disorder. The method is designed for individualized therapy while providing a generalized treatment approach for all Down Syndrome patients.
CRISPR, Down Syndrome, allele-specific, gene therapy
Patent
Inhibitory compounds
Patent published on the 2026-10-01 in WO under Ref WO2026202506 by LOQUS23 THERAPEUTICS LTD [GB] (Hardick David [gb], Reynolds David [gb], Drouhin Pauline [gb])
Abstract: The present invention relates at least in part to certain compounds that function as inhibitors of MutSβ. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which MutSβ activity is implicated, such as, for example, repeat expansion diseases or disorders, as well as to increase the efficiency of genome editing.[...]
Our summary: The invention involves compounds that inhibit MutSβ. It includes methods for preparing these compounds and their pharmaceutical applications. These compounds are relevant for treating repeat expansion diseases and enhancing genome editing efficiency.
inhibitory compounds, MutSβ, pharmaceutical compositions, genome editing
Patent
Application of gene slga3ox4 in cultivation of dwarf and compact plants of tomatoes, and method for cultivating dwarf and compact plants of tomatoes
Patent published on the 2026-09-30 in ZA under Ref ZA202600410 by HORTICULTURE RESEARCH INST SICHUAN ACADEMY OF AGRICULTURAL SCIENCES [CN] (Ma Yanqin [cn], Yang Liang [cn], Zhou Yujie [cn], Song Wenqian [cn], Li Ju [cn], Long Haicheng [cn], Chang Wei [cn], Li Zhi [cn], Gou Gaofeng [cn], Zhong Jian [cn], Miao Mingjun [cn])
Abstract: The present invention belongs to the technical field of gene engineering, and relates to an application of a gene Solanum lycopersicum GA3ox4 (SlGA3ox4) in cultivation of dwarf and compact plants of tomatoes, and a method for cultivating dwarf and compact plants of tomatoes. The present invention provides an application of gene editing of a gene SlGA3ox4 or a reagent for gene editing of a gene SlGA3ox4 in cultivation of dwarf and compact plants of tomatoes. A nucleotide sequence of the gene SlGA[...]
Our summary: The invention involves the application of the SlGA3ox4 gene for cultivating dwarf and compact tomato plants. It details a method for gene editing to achieve these plant characteristics. The nucleotide sequence of the SlGA3ox4 gene is provided for reference.
gene editing, SlGA3ox4, dwarf plants, tomato cultivation
Patent
Biomolecular assay systems and methods for biomolecule isothermal amplification
Patent published on the 2026-09-24 in WO under Ref WO2026197917 by DNAITECH LTD [NZ] (Broom Murray [nz], Gupta Honey [nz], Jaksic Drazen [nz])
Abstract: An isothermal amplification chip for performing Loop-mediated isothermal amplification (LAMP) of a biomolecular target in a sample. The isothermal amplification chip has a sample retainer, including a sample chamber containing an isothermal amplification reaction mix. The sample retainer is located between two heating elements (8, 21) with respect to a stack axis, with the sample chamber in thermal contact with both heating elements (8, 21). The chip has a removable upper sealing layer that is u[...]
Our summary: The content describes a chip designed for Loop-mediated isothermal amplification (LAMP) of biomolecules. It features a sample retainer with a chamber for the amplification reaction mix. The chip includes heating elements and a removable sealing layer for adding CRISPR reagents.
isothermal amplification, LAMP, biomolecular assay, CRISPR
Patent
Gene editing using large insertions
Published on 2026-09-17 by Alexandra Despang @NATURE
Abstract: Nature Biotechnology, Published online: 17 September 2026; doi:10.1038/s41587-026-03319-6While technologies for smaller gene edits, such as base editing, have already entered clinical trials, larger gene cargoes face different challenges, including low editing efficiencies, delivery vehicle size constraints, and possible immunogenicity. Programmable genome engineering systems using recombinases; transposases, including CRISPR-associated transposases (CASTs); genome writing systems; and retrotran[...]
Our summary: The article discusses the challenges of gene editing with large insertions, highlighting issues like low editing efficiencies and delivery constraints. It reviews various programmable genome engineering systems, including recombinases and CRISPR-associated transposases. Experts share insights on strategies to enhance these technologies for therapeutic applications.
gene editing, large insertions, genome engineering, CRISPR
Publication
Improved method for the production of mussel adhesive protein by engineered yeast fermentation
Patent published on the 2026-09-16 in GB under Ref GB2704650 by YOHOLIFE LTD [GB] (Junyu Qian [gb], Aihan Zhang [gb])
Abstract: The invention discloses a method for producing mussel adhesive protein using genetically engineered yeast such as Pichia pastoris; wherein the genetically engineered yeast may comprise mussel adhesive protein genes fp-1 or fp-2, which may be codon-optimised and integrated into yeast using CRISPR-Cas9 technology. The genetically engineered yeast may also comprise genes related to DOPA modification such as tyrosinase. The method for producing the mussel adhesive protein may comprise fermenting the[...]
Our summary: A method for producing mussel adhesive protein using genetically engineered yeast is disclosed. The yeast is modified with mussel protein genes and regulated for protein expression during fermentation. The final product is highly pure and suitable for various applications, including medical and industrial uses.
yeast fermentation, CRISPR-Cas9, mussel adhesive protein, purification methods
Patent
Ethical and Clinical Best Practices for Genome Editing Applications
Published on 2026-02-02 by Mara Ortiz-Bueno, Federica Zinghirino, Pilar Puig Serra, Kyriaki Paschoudi, Lluis Montoliu, Erden Atilla, Yonglun Luo, Alessia Cavazza, Carsten W. Lederer, Karim Benabdellah @MDPI
Abstract: Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders. Several technologies support these advances, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, of which the latter has emerged as the most accessible, versatile, and popular. While GE holds great promise, i[...]
Our summary: Genome editing technologies enable precise DNA modifications for medical treatments. Ethical and regulatory considerations are crucial for safe clinical applications. Regulatory agencies provide guidance on safety, consent, and compliance in genome editing practices.
Genome Editing, Ethical Standards, Regulatory Compliance, Clinical Applications
Publication
